High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma

Fluri, Simon; Ammann, Roland; Lüthy, Annette Ridolfi; Hirt, Andreas; Aebi, Christoph; Duppenthaler, Andrea; Leibundgut, Kurt (2006). High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma. Pediatric blood & cancer, 49(7), pp. 984-987. Hoboken, N.J.: Wiley-Liss 10.1002/pbc.20900

Full text not available from this repository. (Request a copy)

In contrast to adults, autologous stem cell transplantation (ASCT) as part of the salvage strategy after high-dose chemo/radiotherapy in human immunodeficiency virus (HIV) related Non-Hodgkin lymphoma (NHL) is not yet established for children. We report on a 13-year patient with congenital HIV infection and refractory Burkitt lymphoma, who was successfully treated by high-dose therapy (HDT) including rituximab followed by ASCT. After 26 months follow-up the patient remains in complete remission and his HIV parameters have normalized with continued highly active antiretroviral therapy (HAART). HIV infection may no longer exclude children from ASCT as part of salvage therapy. Pediatr Blood Cancer (c) 2006 Wiley-Liss, Inc.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine

UniBE Contributor:

Fluri, Simon; Ammann, Roland; Hirt, Andreas; Aebi, Christoph; Duppenthaler, Andrea and Leibundgut, Kurt

ISSN:

1545-5009

ISBN:

16685736

Publisher:

Wiley-Liss

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:48

Last Modified:

08 Jun 2016 10:39

Publisher DOI:

10.1002/pbc.20900

PubMed ID:

16685736

Web of Science ID:

000250487800020

URI:

https://boris.unibe.ch/id/eprint/19998 (FactScience: 3077)

Actions (login required)

Edit item Edit item
Provide Feedback